Lineage Cell Therapeutics, Inc. develops allogeneic, or “off-the-shelf,” cell therapies for serious medical conditions using its AlloSCOPE cell differentiation and expansion platform. Its pipeline includes OpRegen, also known as RG6501, for geographic atrophy secondary to age-related macular degeneration; OPC1 for spinal cord injury; ReSonance, or ANP1, for hearing loss; and COR1 for corneal endothelial disease.
Recurring company news covers clinical data presentations, preclinical program launches, manufacturing and platform updates, research collaborations, milestone activity, financial results, business updates, and scientific governance. Updates frequently connect Lineage’s cell transplant programs with ophthalmology, neurology, auditory disease, and other non-oncology therapeutic areas.
Lineage Cell Therapeutics announced a $50 million upfront payment from Genentech as part of a collaboration for the development of OpRegen, a cell therapy targeting advanced dry AMD with GA. The total potential payment could reach $670 million, including milestone payments and royalties. Genentech will lead further clinical development, while Lineage will complete current studies and manufacturing tasks. This partnership aims to leverage Genentech's expertise to expedite OpRegen's clinical progress and commercialization.
Lineage Cell Therapeutics (LCTX) announced significant findings from its OpRegen Phase 1/2a clinical study, reporting retinal tissue restoration in four patients with dry age-related macular degeneration (AMD). The areas of geographic atrophy diminished or remained stable over 12 months, and all patients exhibited improvements in visual acuity. Statistically significant differences in visual acuity between treated and untreated eyes were observed at 9, 12, and 15 months. Lineage plans to engage with the FDA regarding OpRegen's development, which has been well tolerated without serious adverse events reported.
Lineage Cell Therapeutics reported positive interim results from its Phase 1/2a clinical trial of OpRegen, a therapy for dry age-related macular degeneration (AMD). Over 12 months, patients in Cohort 4 showed significant improvements in retinal restoration and visual acuity. Specifically, 58% of these patients maintained or improved their vision compared to 67% of untreated eyes. The treatment has been well tolerated, with no new adverse events reported. Lineage plans to engage with the FDA regarding future trials in early 2022.
Lineage Cell Therapeutics (LCTX) reported third quarter 2021 financials, highlighting ongoing clinical advancements in its OpRegen program for dry AMD. Key achievements include positive interim outcomes in 67% of treated patients and a new delivery device for OPC1 trials underway. The company holds $65.1 million in cash and marketable securities. Total revenues rose to $2.3 million, driven by a $1.6 million increase in royalty revenues. Operating expenses totaled $8.1 million. Despite a net loss of $7.8 million, the company is preparing for FDA engagement and clinical trials slated for Q4 2021 and Q1 2022.
Lineage Cell Therapeutics (AMEX:LCTX) is set to report its third quarter 2021 financial and operating results on November 10, 2021, after U.S. market close. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results and provide business updates. Lineage specializes in allogeneic cell therapies targeting significant unmet medical needs, with three key product candidates in development for conditions such as dry age-related macular degeneration and acute spinal cord injuries, presenting billion-dollar market opportunities.
Lineage Cell Therapeutics (LCTX) announced updated interim results from its Phase 1/2a clinical study of OpRegen®, targeting dry age-related macular degeneration (AMD). The study presentation will occur at the 2021 American Academy of Ophthalmology meeting on November 13, 2021. OpRegen has shown ability to halt or reverse geographic atrophy and restore retinal tissue in three patients. The presentation will include data from 24 patients with a minimum 12-month follow-up, highlighting improved baseline vision in the latest cohort.
Lineage Cell Therapeutics (LCTX) announces participation in a fireside chat hosted by B. Riley Securities on 12:30 PM Eastern. The chat will feature company executives including Brian M. Culley and Kevin Cook, and will discuss ongoing cell therapy developments. Notably, the chat aims to highlight therapeutic advancements in treating conditions such as age-related macular degeneration and spinal cord injuries. Interested investors can register to attend the live event today.
Lineage Cell Therapeutics announced statistically significant interim results from its Phase 1/2a study of OpRegen for treating dry age-related macular degeneration (AMD). After 9 to 15 months of follow-up, patients receiving OpRegen showed improved visual acuity compared to untreated eyes, with p-values indicating significance (P = 0.0085 at 9 months). The therapy was well tolerated, with no new adverse effects reported. The results suggest potential for OpRegen to address unmet needs in AMD treatment.
Lineage Cell Therapeutics, a clinical-stage biotechnology firm focused on allogeneic cell therapies, announced that CEO Brian M. Culley will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on September 27 at 4pm ET. Interested parties can register for both live and on-demand presentations on the company's website. Lineage is developing three main products: OpRegen, OPC1, and VAC2, targeting significant health issues like dry age-related macular degeneration and non-small cell lung cancer.
Lineage Cell Therapeutics reported interim results from its Phase 1/2a study of OpRegen, a cell therapy for dry age-related macular degeneration (AMD). Key findings include:
- Zero growth of retinal atrophy in one patient after 33 months.
- 10% reduction in atrophy size noted at 8 months in another patient.
- Average visual acuity improvement of 10.8 letters in treated versus untreated eyes.
OpRegen has shown strong tolerability with no unexpected adverse events, suggesting potential for significant therapeutic outcomes.